title: Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis.
abstract: We treated 21 multiple sclerosis patients with two to four doses of cM-T412, a chimeric monoclonal antibody against the CD4 antigen found on helper/inducer T lymphocytes. The mean number (+/- standard error) of circulating CD4 lymphocytes decreased from 888 (+/- 81) cells/mm3 at baseline to 246 (+/- 18) after treatment. At 1 year after the last treatment, the CD4 count had recovered to only 335 (+/- 32). The antibody had no effect on CD8 lymphocytes, B lymphocytes, or other leukocytes. Side effects were minimal. Despite the prolonged depletion of CD4 lymphocytes, no opportunistic infections occurred. Only 1 patient had a possible allergic reaction. Most patients were clinically stable, but a few progressed. We conclude that repeated treatment with cM-T412 is effective in reducing the number of circulating CD4 lymphocytes and has no limiting side effects.
authors.affiliation: Department of Neurology, Stanford University Medical Center, CA 94305.
authors.forename: J W
authors.initials: JW
authors.lastname: Lindsey
authors.forename: S
authors.initials: S
authors.lastname: Hodgkinson
authors.forename: R
authors.initials: R
authors.lastname: Mehta
authors.forename: D
authors.initials: D
authors.lastname: Mitchell
authors.forename: D
authors.initials: D
authors.lastname: Enzmann
authors.forename: L
authors.initials: L
authors.lastname: Steinman
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015704:CD4 Antigens; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens